Bibliographie

[1] Gaballa SA, Kompella UB, Elgarhy O, et al. Corticosteroids in ophthalmology : drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res 2021 ;11(3):866–93.

[2] Corticoïdes : les points essentiels. PHARMACOMedicale.org (Collège national de pharmacologie médicale). https://pharmacomedicale.org/medicaments/par-specialites/item/corticoides-les-points-essentiels.

[3] Gabison E. Anti-inflammatoires et immunosuppresseurs dans les pathologies de la surface oculaire. In: Baudouin C, Hoang-Xuan T, editors. Pisella PJ. Surface oculaire. Rapport de la Société Française d'Ophtalmologie. Paris: Elsevier Masson ; 2015. p. 541–6.

[4] Dang DH, Riaz KM, Karamichos D. Treatment of non-infectious corneal injury : review of diagnostic agents, therapeutic medications, and future targets. Drugs 2022 ; 82(2) : 145-67.

[5] Schalnus R. Topical nonsteroidal anti-inflammatory therapy inophthalmology. Ophthalmologica 2003 ;217:89–98.

[6] Srinivasan M, Mascarenhas J, Rajaraman R, et al. Visual recovery in treated bacterial keratitis. Ophthalmology 2014 ;126:1310–1.

[7] Butt AL, Chodosh J. Adenoviral keratoconjunctivitis in a tertiary care eye clinic. Cornea 2006 ;25:199–202.

[8] Gabison EE, Huet E, Baudouin C, Menashi S. Direct epithelial-stromal interaction in corneal wound healing : role of EMMPRIN/CD147 in MMPs induction and beyond. Prog Retin Eye Res 2009 ;28:19–33.

[9] Gabison EE, Chastang P, Menashi S, et al. Late corneal perforation after photorefractive keratectomy associated with topical diclofenac : involvement of matrix metalloprotei nases. Ophthalmology 2003 ;110:1626–31.

[10] Lin JC, Rapuano CJ, Laibson PR, et al. Corneal melting associated with use of topical nonsteroidal antiinflammatory drugs after ocular surgery. Arch Ophthalmol 2000 ;118:1129–32.

[11] Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010 ;55:108–33.

[12] Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use : a safety review. Drug Saf 2002 ;25:233–50.

[13] Srinivasan M, Mascarenhas J, Rajaraman R, et al. The steroids for corneal ulcers trial (SCUT) : secondary 12-month clinical outcomes of a randomized controlled trial. Am J Ophthalmol 2014 ; 157 : 327-33.e3.

[14] Srinivasan M, Mascarenhas J, Rajaraman R, et al. Corticosteroids for bacterial keratitis : the Steroids for Corneal Ulcers Trial (SCUT). Arch Ophthalmol 2012 ;130:143–50.

[15] Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010 ;55:108–33.

[16] Renner UD, Oertel R, Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit 2005 ;27:655–65.

[17] Hedayatfar A, Hashemi H, Asgari S, Chee SP. Comparison of efficacy and ocular surface toxicity of topical preservative-free methylprednisolone and preserved prednisolone in the treatment of acute anterior uveitis. Cornea 2014 ;33:366–72.

[18] Brandsdorfer A, Patel SH, Chuck RS. The role of perioperative nonsteroidal anti-inflammatory drugs use in cataract surgery. Curr Opin Ophthalmol 2019 ;30:44–9.

[19] Maca SM, Amon M, Findl O, et al. Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery. Am J Ophthalmol 2010 ;149:777–84.

[20] Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003 ;217:89–98.

[21] Guimaraes de Souza R, Yu Z, Stern ME, et al. Suppression of Th1-mediated Keratoconjunctivitis sicca by lifitegrast. J Ocul Pharmacol Ther 2018 ;34:543–9.

[22] Huang J, Su W, Chen X, et al. Doxycycline attenuates endotoxin-induced uveitis by prostaglandin E2-EP4 signaling. Invest Ophthalmol Vis Sci 2015 ;56:6686–93.

[23] Nissinen L, Kahari VM. Matrix metalloproteinases in inflammation. Biochim Biophys Acta 2014 ;1840:2571–80.

[24] Onghanseng N, Ng SM, Halim MS, Nguyen QD. Oral antibiotics for chronic blepharitis. Cochrane Database Syst Rev 2021 ;6:CD013697.

[25] Qazi Y, Wong G, Monson B, et al. Corneal transparency : genesis, maintenance and dysfunction. Brain Res Bull 2010 ;81:198–210.

[26] Grobe GM, Reichl S. Characterization of vitamin C-induced cell sheets formed from primary and immortalized human corneal stromal cells for tissue engineering applications. Cells Tissues Organs 2013 ;197:283–97.

[27] Lee MY, Chung SK. Treatment of corneal neovascularization by topical application of ascorbic acid in the rabbit model. Cornea 2012 ;31:1165–9.

[28] Chen J, Lan J, Liu D, et al. Ascorbic acid promotes the stemness of corneal epithelial stem/progenitor cells and accelerates epithelial wound healing in the cornea. Stem Cells Transl Med 2017 ;6:1356–65.

[29] Cho YW, Yoo WS, Kim SJ, et al. Efficacy of systemic vitamin C supplementation in reducing corneal opacity resulting from infectious keratitis. Medicine 2014 ;93, e125.